Description of Invention: Novel DNA vaccine constructs against HIV that express highly conserved elements (CE) within the HIV Gag protein and elicit strong, cross-clade cellular and humoral responses. The DNA vaccine vectors were engineered to express CEs for protection against different clades of HIV and prevention of immunodominance, two issues associated with current HIV vaccine candidates.
In vivo studies of Rhesus macaques vaccinated with variants of these constructs expressing seven highly CEs covering >99 of all known Gag sequences elicited strong, cellular T-cell and humoral antibody immune responses. The Gag-specific antibody responses were high titer and cross-clade. Cross-clade protection is important given the sequence diversity of HIV as is the absence of immunodominant epitopes that generate antibodies which are not protective against HIV.
Applications: HIV vaccines
Advantages: Addresses two key hurdles faced by current HIV vaccines: sequence diversity of HIV and immunodominance.
Related Technologies: PCT, Application No. PCT/US01/45624 filed 01 Nov 2001, Reference No. E-308-2000/0 US, Application No. 13/190,969 filed 01 Nov 2001, Reference No. E-308-2000/0
Patent family filed in the U.S., Canada, Australia, Europe, and Japan
For Licensing Information Please Contact: Kevin Chang Ph.D. NIH Office of Technology Transfer 6011 Executive Blvd. Suite 325, Rockville, MD 20852 United States Email: email@example.com Phone: 301-435-5018 Fax: 301-402-0220